TY - JOUR
T1 - Advances in Radioembolization for Liver Cancer
AU - Meiselman, Sam
AU - Thomas, M. Allan
AU - Giardina, J. Daniel
AU - Zheleznyak, Alexander
AU - Thorek, Daniel L.J.
AU - Malone, Christopher D.
N1 - Publisher Copyright:
© 2025 SIR
PY - 2025/12
Y1 - 2025/12
N2 - Radioembolization, most commonly in the form of transarterial delivery of microspheres embedded or loaded with yttrium-90, has evolved to become a highly effective and versatile treatment modality for both primary and metastatic liver cancers. Refinements in patient selection and dosimetry have advanced this therapy as a frontline choice in many clinical scenarios. Despite this, certain limitations restrain the full potential of this therapy and its application to liver cancer and solid tumors in other organs. Recent preclinical advances in image-guided delivery of cancer therapeutics seek to improve upon the existing platform of radioembolization. These include codelivery of agents that harness untapped tumoricidal sources of radionuclides including nanophotosensitizers, chemotherapeutics, immune adjuvants, and photothermal agents. Alternative radionuclides such as alpha emitters can also be locally delivered using image guidance. This review details some of these preclinical advances.
AB - Radioembolization, most commonly in the form of transarterial delivery of microspheres embedded or loaded with yttrium-90, has evolved to become a highly effective and versatile treatment modality for both primary and metastatic liver cancers. Refinements in patient selection and dosimetry have advanced this therapy as a frontline choice in many clinical scenarios. Despite this, certain limitations restrain the full potential of this therapy and its application to liver cancer and solid tumors in other organs. Recent preclinical advances in image-guided delivery of cancer therapeutics seek to improve upon the existing platform of radioembolization. These include codelivery of agents that harness untapped tumoricidal sources of radionuclides including nanophotosensitizers, chemotherapeutics, immune adjuvants, and photothermal agents. Alternative radionuclides such as alpha emitters can also be locally delivered using image guidance. This review details some of these preclinical advances.
UR - https://www.scopus.com/pages/publications/105021875160
U2 - 10.1016/j.jvir.2025.07.018
DO - 10.1016/j.jvir.2025.07.018
M3 - Comment/debate
C2 - 41276366
AN - SCOPUS:105021875160
SN - 1051-0443
VL - 36
SP - 1876
EP - 1881
JO - Journal of Vascular and Interventional Radiology
JF - Journal of Vascular and Interventional Radiology
IS - 12
ER -